IBD and hepatobiliary disease (primary sclerosing cholangitis)
Hepatobiliary involvement is seen in 10% to 15% of
children and adolescents who have inflammatory bowel disease and is among the
most common extraintestinal manifestation associated with these disorders.
The nature of the relationship between inflammatory bowel disease and
hepatobiliary disease remains unclear. Although the course of the
liver disease usually is mild, it is more severe in patients who have ulcerative
colitis than Crohn disease. The
findings associated with these disorders include fatty infiltration, primary
chronic hepatitis, cirrhosis, and
Although biochemical or histologic abnormalities such as fatty infiltration and pericholangitis of the liver are found in approximately 50% of pediatric patients who have ulcerative colitis, only 10% to 14% of these children become symptomatic, with jaundice and pain being uncommon. Children who have hepatobiliary involvement are at risk for malignancy (biliary tract carcinoma) and may require liver transplantation. Some studies suggest that the incidence of severe liver damage is higher among patients who have pancolitis than among those in whom disease involvement is limited to the descending colon.
Primary sclerosing cholangitis develops in 3% of children who have inflammatory bowel disease. Chronic ulcerative colitis more often is associated with sclerosing cholangitis than is Crohn disease, representing 74% of the cases. It may be present during the initial evaluation for inflammatory disease in up to 20% of patients; only 50% of children who have sclerosing cholangitis have inflammatory bowel disease. Sclerosing cholangitis is characterized by fibrosis and inflammation of the intrahepatic and extrahepatic bile ducts, leading to bile duct obliteration and hepatic failure. The etiology is unknown, but it probably is mediated immunologically. Presenting symptoms include abdominal pain, fatigue, weight loss, jaundice, and pruritus, as described for the boy in the vignette. Patients who have primary sclerosing cholangitis have elevated serum aminotransferase and gamma glutamyl transferase and direct bilirubin concentrations. Antinuclear and anti-smooth muscle antibodies are present in most patients. Endoscopic retrograde cholangiopancreatography (ERCP) is the diagnostic procedure of choice. The pathognomonic findings at ERCP include diffusely distributed multifocal strictures alternating with dilated or normal segments. Treatment of primary sclerosing cholangitis includes immunosuppression, ursodeoxycholic acid, antibiotics, and liver transplantation, although none has proved palliative or curative.
Although cholelithiasis, hepatic abscess, and hepatitis B infection can occur in patients who have inflammatory bowel disease, none of these disorders occurs more commonly in patients who have either ulcerative colitis or Crohn disease.
Classen M, Gotze H, Richter HJ, Bender S. Primary sclerosing
cholangitis in children. J Pediatr Gastroenterol Nutr. 1987;6:197-202
Desmet VJ, Geboes K. Liver lesions in inflammatory bowel disease. J
Hyams J, Markowitz J, Treem W, et al. Characteristics of hepatic
abnormalities in children with inflammatory bowel disease. Inflamm
Bowel Dis. 1995;1:27-33
Kane W, Miller K, Sharp HL. Inflammatory bowel disease presenting as
liver disease during childhood. J Pediatr. 1980;97:775-778
Vierling JM. Hepatobiliary complications of ulcerative colitis and
Crohn disease. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of
Liver Disease. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1990: